



PSIOXUS THERAPEUTICS NAMED MOST INNOVATIVE BIOTECH SME 2013 BY EUROPABIO

British company selected based on innovative approach to cancer therapy and solid business strategy

OXFORD, UK – October 7, 2013 – [PsiOxus Therapeutics, Ltd.](#) (PsiOxus), a development stage biotechnology company, has been named this year's Most Innovative Biotech SME by [EuropaBio](#) as part of the first ever [European Biotechnology Week](#). The award is in recognition of the innovative approaches the company is taking to develop new therapeutics for treating cancer and other related diseases such as cachexia and sarcopenia. This includes a new class of oncolytic vaccines that selectively target and destroy cancer cells but leave healthy cells untouched.

EuropaBio was created in 1996 to facilitate and promote the success of the biotech industry in Europe. Regarding the recent award, EuropaBio SME Platform chair, Tom Saylor, said: "The creative innovation behind PsiOxus Therapeutics' novel approach to cancer therapy and its solid business strategy are an outstanding example of innovative biotech in Europe. At EuropaBio, we are delighted to give a platform to such companies and the truly fantastic work that they do in helping to meet societal grand challenges of healthy aging and safeguarding the environment."

Dr. John Beadle, CEO of PsiOxus Therapeutics, commented: "It is a great honor for PsiOxus to receive this award in recognition of our work creating highly selective anti-cancer agents such as [ColoAd1](#). In the case of this therapeutic, we've been able to develop a patented process that harnesses the power of directed evolution to identify and optimize virus strains, the likes of which are unlikely to have ever been discovered using traditional 'rational design' approaches."

ColoAd1 is the lead virus from this process and it selectively propagates inside cancer cells, causing them to die by membrane disruptive lysis. For each cancer cell infected, an oncolytic vaccine can produce thousands of copies of itself that then spread to nearby cancer cells and kill them too. At the same time, the dying cancer cells provoke an immune response that further amplifies the process within the tumor environment, representing a new generation of 'self-amplifying' cancer therapies.

As part of the Most Innovative Biotech SME award, PsiOxus will receive €10,000 and a complementary two year membership of EuropaBio. The prize is also highly indicative of the exciting times and bright future being enjoyed by the company, with ColoAd1 currently being evaluated as part of two separate Phase II clinical trials, with preliminary results due at the end of the year.

About PsiOxus Therapeutics, Ltd.

PsiOxus Therapeutics is an Oxford, UK-based development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases. ColoAd1 is an oncolytic vaccine for the systemic treatment of metastatic cancer, which has demonstrated exceptional anti-cancer properties in late pre-clinical development and is now in phase II clinical development. MT-102 is a dual action Anabolic Catabolic Transforming Agent (ACTA) in phase II clinical development for the treatment of cachexia and sarcopenia. The Company is also developing treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.

Dr. John Beadle is CEO of PsiOxus. Dr. Beadle was previously a co-founder of PowderMed, which was sold to Pfizer, Inc. for more than \$300 million in 2006. Dr. Michael Moore, the former CEO of Piramed, which was acquired by Roche in 2008, serves as Chairman of the Board of Directors.

PsiOxus is advised by a distinguished Scientific Advisory Board that includes Prof Stefan Anker (Professor of Cardiology and Cachexia Research at Charité Medical School, Berlin and President of the Society on Sarcopenia, Cachexia and Wasting Diseases), Prof Andrew Coats (Norwich Research Park Professor-at-Large, University of East Anglia), Prof Len Seymour (Chair of Gene Medicine at Oxford University and Secretary General of the European Society for Gene and Stem Cell Therapy), and Dr. Kerry Fisher (an internationally-recognized specialist in molecular medicine, also of Oxford University).

Contacts:

PsiOxus Therapeutics
Dr. John Beadle, Chief Executive Officer
Tel +44 (0) 7810 770 310
John.Beadle@psioxus.com

US Media Enquiries:
Erik Clausen, Chempetitive Group
Tel +1 781-608-7091 or +1 310-463-9383
PsiOxus@chempetitive.com

UK Media Enquiries:
Dr. Paul Avery, Chempetitive Group Europe
Tel: +44(0)1223 828202
pavery@chempetitive.com

###